

REMARKS

Claims 1-7 have been canceled without prejudice or disclaimer. Claims 8-20 have been added and therefore are pending in the present application. Claims 8-20 are supported by original claims 1-7.

This application contains a Sequence Listing. Applicants enclose a computer-readable form of the Sequence Listing. The content of the paper copy of the Sequence Listing and of the computer readable form is the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Date: December 19, 2005

Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097